3D Printed Drugs Market

3D Printed Drugs Market - By Technique Type, By Dosage Form, By Scenario, By Drugs, By Applications, By End-Users and Global Region Market Size, Share, Opportunity & Forecast 2020-2025

Request Sample Request Discount
  • Status : Ongoing
  • Published on: Feb 2021
  • Report ID: KDMI-3363
  • Available Format: PDF/Excel/DOC


Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the 3D Printed Drugs Market

Request Sample

3D Printed Drugs are referred to medications which are designed or manufactured by the 3D printing technique by solidifying layers of materials to form a definite 3D structure and which have unitary porous structures that readily disperse in the mouth. Being very permeable to fluids, these drugs dissolve as soon as they meet a small quantity of liquid. This type of medication helps controlling the delivery of medications to children, physically impaired patients, patients who often have swallowing difficulties, and those dealing with the complications of strokes and other neurological disabilities.

3D printed drugs enable the creation of drugs keeping into account individual’s specific requirements and can also be created in line with certain preferences. Additionally, with 3D printed drugs, benefits of multiple treatments with a single pill can also be enjoyed.

In 3D printed technology, factors like the size, shape, dose, appearance, and rate of delivery of a drug can be controlled or adjusted which makes it a highly innovative, reliable and cost-saving technology to deliver medications with convenience.

The global 3D printed drugs market is expected to grow at a CAGR of around 9.1% over the course of next 5 years.


The growth of this market is attributed towards major relying factors including; the proliferating global demand for instantaneous soluble drugs which can disperse in the mouth easily, the growing prevalence of dysphagia worldwide, the increasing usage and adaptability of 3D printing technology in the medical & healthcare industries, the increasing integration of 3D printing with conventional pharmaceutical technologies coupled with the growing production of combination medicine and the growing number of improvements in the health care infrastructure etc.

Additionally, 3D printing also caters to the arrival of individualized drugs, also known as personalized or customized drugs. These drugs are customizable i.e., designed specifically taking into account individual patient’s medical history and are accordingly much more effective and efficient than batch-produced drugs. Also, since the Precision Medicine's Initiative was released in the US in 2015, pharmaceutical research organizations have been proactively pursuing the development of more customized treatments since then to make medicines safer and more effective. This increase in demand and adoption of medicine customization and personalization will aid in the growth of the 3D Printed Drugs market comprehensively soon.

Moreover, the 3D Printed Drugs industry has been witnessing colossal number of technological advancements in 3D printing technique since its commencement. To able to cater to the massively augmenting demand, new players are seen to enter the market with highly advanced and innovative technologies. The increasing launch of new and technologically advanced products provides ample opportunities for the growth of the overall 3D printed drugs market.

Furthermore, other factors such as the high prevalence of chronic diseases and other health related disorders, the rising geriatric population coupled with increasing incidence of epilepsy cases, the surging awareness regarding the 3D printing technology and its advantages in the developing countries and the rising demand for cheaper drugs further enhance the growth of this market. With that, the flaws in conventional medicines such as disparate qualities of the final products with respect to drug loading, drug release, drug stability and pharmaceutical dosage further contributes in the expansion of this market.

However, factors such as the adverse side effects pertaining to the use of 3D printed drugs, lack of government regulations, usage of 3D printing to develop illegal drugs, high investment for continuous clinical development of 3D printing and complex clinical trial protocols, concerns relating to data security and privacy, mislabeling of blueprints and the lack of approval of 3D printed drugs in many countries impede the growth of this market.


By Technique Type:

  • Fused Deposition Modeling
  • Inkjet Printing Infant
  • Zip Dose
  • Direct Write
  • Powder Bed Printing
  • Selective Laser Sintering
  • Stereolithography
  • Others

By Dosage Form:

  • Tablets
  • Capsules
  • Multi Drug Implant
  • Nanoparticles
  • Solutions
  • Others

By Scenario:

  • Low Growth Scenario
  • Moderate Growth Scenario
  • Rapid Growth Scenario

By Drugs:

  • Spritam
  • Others

By Applications:

  • Neurology
  • Orthopedic
  • Hearing and Audibility Aid
  • Dental
  • Medical Implants
  • Others

By End-Users:

  • Hospitals
  • Clinics
  • Research Laboratories
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa


The North American region along with the Asia Pacific region dominates the 3D printed drugs market. The growth of the market in the North American region can be attributed to factors such as the high prevalence of chronic disorders in the region, the presence of advanced domestic healthcare infrastructure in the region, the increasing investments in R&D activities in the region, the rising adoption of technological advancements in 3D printing and also the increasing geriatric population in the region. Moreover, with Aprecia Pharmaceuticals successfully getting the FDA approval of their first 3D printed drug, Spritam, which is also the only approved drug as of now, this region’s market size is expected to multifold in the near future. The U.S is the major contributor in the region.

The Asia Pacific region on the other hand along with ranking at the top, is also the fastest growing regional market, the growth of which can be accounted to factors such as the surging awareness regarding the 3D printing technique in the region, the ongoing developments in the healthcare infrastructure coupled with the high growth of the pharmaceutical industry in this region, the proliferating patient pool in the region, the propelling investments in the pharmaceutical industry coupled with the increasing investment in research and development in healthcare sector and the growing disposable income of the populace  etc.  The major contributors in the region include India and China.

The European region also holds a prominent share in the 3D Printed Drugs market and is projected to grow robustly in the years to come. The growth in the region can be attributed to factors such as the increasing presence of well-established healthcare systems in the region, the growing prevalence of dysphagia in the region, the surging adoption of 3D printed drugs in the region, the rising health consciousness among people and the increasing R&D activities and investments in the healthcare sector of this region etc.


  • 3D Printer Drug Machine
  • Hewlett Packard Caribe
  • BV LLC
  • GlaxoSmithKline Plc.
  • FabRx Ltd.
  • Cycle Pharmaceuticals
  • Merck KGaA
  • Tvasta
  • Triastek
  • Aprecia Pharmaceuticals
  • Other Players


  1. In February 2021, The Food and Drug Administration (FDA) approved the Patient Specific Talus Spacer (Additive Orthopaedics) for humanitarian use in the treatment of avascular necrosis (AVN) of the ankle joint. The Patient Specific Talus Spacer is said to be a first-of-its-kind 3D-printed implant for talus replacement individually designed for each patient using computed tomography (CT) imaging. The approval is said to be supported by data from 31 patients and 32 talus replacement surgeries; 1 patient had operations on both ankles.
  2. In February 2021, Chinese pharmaceutical and 3D printing technology firm Triastek received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for its first 3D printed drug product, T19.

Custom Research Requirement? Questions to ask?

Get in touch

Custom Research requirement.

Go Up